Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

Lorentzen, Cathrine Lund; Haanen, John B.A.G.; Met, Özcan; Svane, Inge Marie

doi:10.1016/s1470-2045(22)00372-2

Cited by 229 publications

(217 citation statements)

References 55 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…Recently, mRNA‐based vaccines have shown promising advantages (e.g. easily tolerated, no genome integration, non‐infectious, activation of objective immune responses and fast and inexpensive production) against cancers 30,31 . Targeting the tumour‐specific mutational genes associated with tumour immunity personalizes the anti‐tumour treatment 28,29 .…”

Section: Discussionmentioning

confidence: 99%

“…easily tolerated, no genome integration, non-infectious, activation of objective immune responses and fast and inexpensive production) against cancers. 30,31 Targeting the tumourspecific mutational genes associated with tumour immunity personalizes the anti-tumour treatment. 28,29 Sahin et al conducted comparative exome and RNA sequencing in stage III/IV melanoma patients' samples to identify non-synonymous mutations for mutation-encoding RNA selection, and they further discovered the tumourassociated self-antigen and manufactured the neoepitopes manually.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of tumour antigens and immune subtypes in the development of an anti‐cancer vaccine for endometrial carcinoma

Feng

2023

Scand J Immunol

View full text Add to dashboard Cite

Therapeutic application of vaccines to endometrial carcinoma (EC) remains uncertain. In this study, we aimed to identify potential tumour antigens for use in the development of an anti-tumour mRNA vaccine and clarify immune subtypes and their characteristics for immunotherapeutic application in heterogeneous EC by integrating multi-omics data. Importantly, four potential tumour antigen candidates-PGR, RBPJ, PARVG and MSX1-were identified and significantly correlated with better overall survival, disease-free survival and distinct antigenpresenting cell infiltration in EC. In addition, two different immune subtypes by consensus clustering analysis of the immune-related genes were identified.Patients with C2 immunophenotypes exhibited superior survival outcomes and 'hot' immunoreactivity and harboured higher microsatellite instability scores and tumoral mutation burden but lower copy-number variation burden. Furthermore, the distinct expression of immunogenic cell death modulators and differential microenvironmental characteristics of immune-cell infiltration were also revealed between C1 and C2 immune-subtype tumours. Enrichment analysis of the co-expression of immune-related genes showed enrichment in immune response, immune cell-mediated immunity and antigen processing pathways. These results indicated that these identified tumour antigens can be used for developing antitumour mRNA vaccines, and tumours with C2 immunophenotypic characteristics demonstrated sensitivity and susceptibility to immunotherapy in EC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Identification of tumour antigens and immune subtypes in the development of an anti‐cancer vaccine for endometrial carcinoma

Feng

2023

Scand J Immunol

View full text Add to dashboard Cite

show abstract

“…mRNA vaccines have thus targeted many different types of cancers targeting both tumor-associated and tumor-specific antigens. The dozens of studies can be found at and useful summary tables based on differences in formulation and phase of study can be found in a recent review [ 70 ]. mRNA encoding tumor antigens are also being tested in combination with other means to drive immune responses, such as combining the mRNA with other immune modalities such as checkpoint inhibitors.…”

Section: Dna and Mrna Immunotherapeutic Vaccines Under Developmentmentioning

confidence: 99%

DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress

Liu

2022

Cancers

View full text Add to dashboard Cite

Interest in the capabilities of nucleic acid vaccines, (DNA and mRNA vaccines) for both prophylactic and therapeutic uses have greatly increased following the successful deployment of two mRNA and, on a more limited scale, one DNA vaccine for COVID-19. In addition to targeting other pathogens for prophylactic vaccines, efforts are also being made towards using them for therapies for chronic infections and cancer. An examination of past and current successes for such therapies using other technologies with an emphasis on the immunological mechanisms will be provided followed by an assessment of the relevant characteristics of DNA and mRNA vaccines to predict their utility for therapies for chronic viral infections and cancer. Efforts and progress for these targets will be described.

show abstract

“…This adaptability illustrates the potential of the IVT mRNA technology for use in future vaccines against emerging infectious diseases. Beyond vaccines for infectious diseases, many clinical programs are in progress for cancer immunotherapy or with mRNA-based medicines acting as a therapeutic modality, including mRNA as a template for gene editing enzymes 3 , 4 , 5 .…”

Section: Introductionmentioning

confidence: 99%

The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case

Blenke

Örnskov²,

Schöneich³

et al. 2023

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

Cited by 229 publications

References 55 publications

Identification of tumour antigens and immune subtypes in the development of an anti‐cancer vaccine for endometrial carcinoma

Identification of tumour antigens and immune subtypes in the development of an anti‐cancer vaccine for endometrial carcinoma

DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress

The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case

Contact Info

Product

Resources

About